Literature DB >> 2610503

Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients.

C A Hirata1, D R Guay, W M Awni, D J Stein, P K Peterson.   

Abstract

The steady-state pharmacokinetics of ciprofloxacin were evaluated in nine elderly patients with lower respiratory tract infections after an intravenous dosage regimen of 200 mg every 12 h (n = 9) and an oral dosage regimen of 750 mg every 12 h (n = 6). Ciprofloxacin concentrations in serum and urine were measured by high-performance liquid chromatography. The peak concentration in serum, total body clearance (CLs), steady-state volume of distribution (Vss), and terminal elimination half-life after intravenous dosing were 3.5 +/- 0.8 micrograms/ml, 4.38 +/- 1.80 ml/min per kg, 1.6 +/- 0.6 liters/kg, and 5.8 +/- 2.4 h, respectively. The peak concentration in serum, time to peak concentration in serum, absorption lag time, and absolute bioavailability (F) after oral dosing were 7.6 +/- 2.2 micrograms/ml, 1.9 +/- 1.0 h, 0.4 +/- 0.5 h, and 7.7 +/- 24.2%, respectively. The elevated drug concentrations in serum samples from the elderly after oral dosing, compared with data obtained from younger subjects, appear to be a function of reduced CLs, renal clearance, and Vss. The increased F observed in some patients may be due to the effect of concomitant or proximate administration of tube feedings, medications which may alter gastric motility or acidity, or decreased first-pass metabolism. The results demonstrate that factors related to age and declining renal function, rather than infectious disease state, may be primary in determining alterations in pharmacokinetic parameters in the elderly. In elderly patients with normal renal function for their age, no dosage adjustment for intravenous or oral ciprofloxacin is necessary.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2610503      PMCID: PMC172789          DOI: 10.1128/AAC.33.11.1927

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration.

Authors:  K Borner; G Höffken; H Lode; P Koeppe; C Prinzing; P Glatzel; R Wiley; P Olschewski; B Sievers; D Reinitz
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

3.  Pharmacokinetics of ciprofloxacin in elderly subjects.

Authors:  M LeBel; G Barbeau; M G Bergeron; D Roy; F Vallée
Journal:  Pharmacotherapy       Date:  1986 Mar-Apr       Impact factor: 4.705

4.  Determination of ciprofloxacin and its 7-ethylenediamine metabolite in human serum and urine by high-performance liquid chromatography.

Authors:  W M Awni; J Clarkson; D R Guay
Journal:  J Chromatogr       Date:  1987-08-07

5.  Pharmacokinetics of ciprofloxacin in the elderly.

Authors:  A Bayer; A Gajewska; M Stephens; J M Stark; J Pathy
Journal:  Respiration       Date:  1987       Impact factor: 3.580

6.  Dose- and sex-independent disposition of ciprofloxacin.

Authors:  D Höffler; A Dalhoff; W Gau; D Beermann; A Michl
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

8.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

9.  Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin.

Authors:  B Ledergerber; J D Bettex; B Joos; M Flepp; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

10.  Tissue penetration of ciprofloxacin after single and multiple doses.

Authors:  M LeBel; F Vallée; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

View more
  10 in total

Review 1.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 2.  Key Factors in Effective Patient-Tailored Dosing of Fluoroquinolones in Urological Infections: Interindividual Pharmacokinetic and Pharmacodynamic Variability.

Authors:  Oskar Estradé; Valvanera Vozmediano; Nerea Carral; Arantxa Isla; Margarita González; Rachel Poole; Elena Suarez
Journal:  Antibiotics (Basel)       Date:  2022-05-11

Review 3.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

4.  Pharmacokinetics of cefepime in patients with respiratory tract infections.

Authors:  J M Kovarik; J C ter Maaten; C M Rademaker; M Deenstra; I M Hoepelman; H C Hart; G R Matzke; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 5.  Quinolone disposition in the elderly. Practical implications.

Authors:  I Nilsson-Ehle; B Ljungberg
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

6.  Crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in healthy elderly volunteers.

Authors:  M P Weinstein; R G Deeter; K A Swanson; J S Gross
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

7.  Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.

Authors:  A Forrest; C H Ballow; D E Nix; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

Review 8.  A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.

Authors:  Jan-Frederik Schlender; Donato Teutonico; Katrin Coboeken; Katrin Schnizler; Thomas Eissing; Stefan Willmann; Ulrich Jaehde; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

9.  Uremic Toxins and Ciprofloxacin Affect Human Tenocytes In Vitro.

Authors:  Erman Popowski; Benjamin Kohl; Tobias Schneider; Joachim Jankowski; Gundula Schulze-Tanzil
Journal:  Int J Mol Sci       Date:  2020-06-14       Impact factor: 5.923

10.  Fluoroquinolone resistant bacterial isolates from the urinary tract among patients attending hospitals in Bushenyi District, Uganda.

Authors:  Martin Odoki; Adamu Almustapha Aliero; Julius Tibyangye; Josephat Nyabayo Maniga; Emmanuel Eilu; Ibrahim Ntulume; Eddie Wampande; Charles Drago Kato; Ezera Agwu; Joel Bazira
Journal:  Pan Afr Med J       Date:  2020-06-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.